A Case of Insulin Edema Syndrome Improved by Weekly Insulin
Abstract
Insulin edema is a rare complication of insulin therapy, typically occurring during treatment initiation or intensification. We report a 55-year-old woman with a longstanding diagnosis of type 2 diabetes (hemoglobin A1c 11.8% [4.3%-6.0%]) with low adherence to insulin therapy due to the rapid onset of peripheral edema and weight gain following insulin injections. Secondary etiologies of edema were ruled out, and she was diagnosed with insulin edema syndrome. Various types of insulin were tried, including an automated insulin delivery, which worsened her edema and weight gain, leading to discontinuation of all insulins. She was later diagnosed with latent autoimmune diabetes in adults. Weekly insulin icodec was introduced, which was well-tolerated by the patient and improved her adherence to therapy and her insulin edema without significant weight gain. Insulin edema is a diagnosis of exclusion, and clinicians should be aware of this clinical entity. The use of third-generation long-acting insulin analog may be helpful in some patients with this syndrome.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.